OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”) today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange ...
Following its April 2025 Discussion Paper, “Shaping the Future of AIM", the London Stock Exchange (the Exchange) has published a feedback statement outlining its roadmap for AIM. This plan combines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results